Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET’s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5–2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead.

You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin

Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard, From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

See omnystudio.com/listener for privacy information.

Habil Khorakiwala on India's First FDA-Approved Antibiotic.

The Morning Brief

Habil Khorakiwala on India's First FDA-Approved Antibiotic.